NCT06014502 is a Phase 1 clinical trial of IMGS-001 in Solid Tumor, sponsored by ImmunoGenesis.

Who is sponsoring NCT06014502?

NCT06014502 is sponsored by ImmunoGenesis.

What drugs are being tested in NCT06014502?

Interventions in NCT06014502: IMGS-001.

What condition does NCT06014502 study?

NCT06014502 studies Solid Tumor.

Is NCT06014502 still recruiting?

NCT06014502 is currently recruiting now. Last updated 6 May 2026.

Last reviewed 2026-05-06 · How we verify

NCT06014502

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients With Relapsed or Refractory Advanced Solid Tumors

Recruiting now Phase 1 Last updated 6 May 2026

What this trial tests

Phase 1 trial testing IMGS-001 in Solid Tumor in 105 participants. Currently enrolling.

Timeline

7 September 2023

Primary endpoint
1 December 2026

1 December 2027

Quick facts

Lead sponsor	ImmunoGenesis
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	105
Start date	7 September 2023
Primary completion	1 December 2026
Estimated completion	1 December 2027
Sites	6 locations across United States

Drugs / interventions tested

IMGS-001 — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

ImmunoGenesis — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Phase 1a- Safety and tolerability of IMGS-001 by dose-limiting toxicities and adverse events
Time frame: 21 days
Frequency and severity of dose limiting toxicities and adverse events
Phase 1b- Recommended Phase 2 dose (RP2D) of IMGS-001 for specified tumor-specific cohorts as a pharmacologically optimal dose (POD)
Time frame: 12 months
RP2D will be defined by pooling all available PK, PD, target engagement, efficacy, safety, and tolerability data from Part 1 and Part 2

Sponsor's own description

The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their cancer. Phase 1a (Part 1) will test the safety of five different doses of IMGS-001 to use in further studies. Patients with cancer that have advanced or spread to other parts of the body following treatment with other available therapies will be treated in Part 1. Phase 1b (Part 2) will test two doses of IMGS-001 identified in Part 1 to further determine the safety and potential effectiveness in select cancer types.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06014502 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ImmunoGenesis
Last refreshed: 6 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06014502.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing